Subfocus

Quantifying Fluid in AMD

Central subfoveal thickness isn’t the only biomarker clinicians can use to track disease progression and treatment effect.

Stela Vujosevic, MD, PhD, FARVO, FEBO

Clinical Trial Designs in Wet AMD: A Brief Review

Can newer therapies improve upon visual acuity and other outcomes for patients?

Carl D. Regillo, MD

The Effect of Biosimilars on Clinical Practice

A look at the true cost of the new drugs that are shaking up our therapeutic approaches.

Margaret M. Runner, MD, and George A. Williams, MD